Meta analysis of brain metastases ideal treatment mode

Abstract

Abstract:ObjectiveTo explore the ideal treatment mode of brain metastases by Metaanalysis. MethodsArticles were searched for from the databases at home and abroad using English and Chinese keywords. Searching time limited from the databases setting up to December 30, 2012. Jadad score was applied to evaluate the qualities of literatures. RevMan5.0 software was applied to perform the Metaanalysis. A totle of 25 articles including 2 750 patients were eligible for the Metaanalysis, which divided into groups with different treatment. ResultsCompared with monotherapy, combined therapy improved 1year survival (OR=0.58, 95%CI： 0.46~0.71， P＜0.000 01). In combined therapy groups, compared with two methods, three kinds of therapies improved 1year survival (OR=0.63, 95%CI： 0.50~0.80， P=0.000 1). Compared with local therapy only or systemic therapy only, systemic combined local therapy improved 1year survival (OR=0.68, 95%CI： 0.53~0.86， P=0.001; OR=0.59, 95%CI： 0.41~0.86， P=0.006). In systemic combined local therapy groups, three kinds of treatments improved 1year survival compared with two methods (OR=0.52, 95%CI： 0.35~0.78， P=0.002). Compared with nonmolecular targeted therapy, molecular targeted therapy improved 1year survival (OR=0.76, 95%CI： 0.67~0.87， P＜0.000 1). ConclusionThe reasonable treatment for patients with brain metastases is combined treatment with operation, radiotherapy and chemotherapy. There is better curative effect added molecular targeted therapy based on original scheme, if patients have targeted therapy indications.

Key words:Meta-analysis,Antineoplastic protocols,Survival rate,Brain metastases

Li Ying, Fang Xiaomeng, Jiang Da, Dong Qian, Zhang Zengye, Zheng Fei. Meta analysis of brain metastases ideal treatment mode[J]. Journal of International Oncology, 2015, 42(2): 103-108.

References

［1］ Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology［J］. J Neurooncol, 2005, 75(1): 5-14. ［2］ Fabi A, Felici A, Metro G, et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center［J］. J Exp Clin Cancer Res, 2011, 30: 10. ［3］ Antonadou D, Paraskevaidis M, Sarris G, et al. Phase Ⅱ randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases［J］. J Clin Oncol, 2002, 20(17): 3644-3650. ［4］ Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebralmetastasis［J］. Cancer, 1996, 78(7): 1470-1476. ［5］ Postmus PE, HaaxmaReiche H, Smit EF, et al. Treatment of brain metastases of smallcell lung cancer: comparing teniposide and teniposide with wholebrain radiotherapy a phase Ⅲ study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group［J］. J Clin Oncol, 2000, 18(19): 3400-3408. ［6］ Chua D, Krzakowski M, Chouaid C, et al. Wholebrain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from nonsmallcell lung cancer: a randomized, openlabel phase Ⅱ study［J］. Clin Lung Cancer, 2010, 11(3): 176-181. ［7］董丽华, 刘军, 刘锋. 非小细胞肺癌脑转移综合治疗的探讨［J］. 中风与神经疾病杂志, 2005, 22(4): 362. ［8］马明, 赵建, 王中彬. 非小细胞肺癌脑转移的治疗［J］. 辽宁医学院学报, 2007, 28(2): 40-42. ［9］ Guerrieri M, Wong K, Ryan G, et al. A randomized phase Ⅲ study of palliative radiation with concomitant carboplatin for brain metastases from nonsmall cell carcinoma of the lung［J］. Lung Cancer, 2004, 46(1): 107-111. ［10］ Le Scodan R, Jouanneau L, Massard C, et al. Brain metastases from breast cancer: prognostic significance of HER2 overexpression, effect of trastuzumab and cause of death［J］. BMC Cancer, 2011, 11: 395. ［11］石玉生, 张兴梅. 163例脑转移瘤疗效分析［J］. 第一军医大学学报, 1999, 19 (3): 269-271. ［12］ Neuhaus T, Ko Y, Muller RP, et al. A phase Ⅲ trial of topotecan and whole brain radiation therapy for patients with CNSmetastases due to lung cancer［J］. Br J Cancer, 2009, 100(2): 291-297. ［13］夏建洪, 陈立春, 乔岩, 等. 替加氟同步放疗治疗消化道肿瘤脑转移效果观察［J］. 武警医学, 2012, 23(7): 580-583. ［14］ Zeng YD, Zhang L, Liao H, et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from nonsmallcell lung cancer: a retrospective study［J］. Asian Pac J Cancer Prev, 2012, 13(3): 909-914. ［15］于永江, 刘穗媛. 脑转移瘤治疗方法的选择和疗效分析［J］. 中国现代医生, 2009, 47(32): 14-15. ［16］梁艺湖, 麦洁文. 不同方法治疗脑转移瘤5l例疗效分析［J］. 广东医学院学报, 2000, 18(1): 102-104. ［17］张东兴, 卢宜民. 放射治疗联合拓朴替康治疗肺癌脑转移34例［J］. 中国实用医刊, 2011, 38(19): 99-101. ［18］张湘衡, 夏云飞, 牟永告, 等. 168例脑转移瘤病例分析［J］. 广东医学, 2002, 23(1): 12-13. ［19］董明新, 赵彤, 黄京子, 等. 非小细胞肺癌脑转移瘤治疗方案的优化选择［J］. 中华放射医学与防护杂志, 2006, 26(4): 371-373. ［20］何安泰. 肺癌脑转移患者长期生存分析［J］. 中国厂矿医, 2008, 21(6): 649-651. ［21］周忠清, 梁冶矢, 张劲松, 等. 脑转移瘤的外科治疗［J］. 医师进修杂志, 2004, 27(10): 15-17. ［22］乔建. 脑转移瘤120例诊治分析［J］. 陕西医学杂志, 2006, 35(9): 1102-1105. ［23］ Kim KH, Lee J, Lee JI, et al. Can upfront systemic chemotherapy replace stereotactic radio surgery or whole brain radiotherapy in the treatment of nonsmall cell lung cancer patients with asymptomatic brain metastases［J］. Lung Cancer, 2010, 68(2): 258-263. ［24］鲁继斌, 苏守元. 肺癌脑转移140例临床资料分析［J］. 中国肿瘤临床, 1993, 20(4): 269-272. ［25］ Sandler A, Gray R, Perry MC, et al. Paclitaxelcarboplatin alone or with bevacizumab for nonsmallcell lung cancer［J］. N Engl J Med, 2006, 355(24): 2542-2550. ［26］黄忠连, 杨震, 李超. 非小细胞肺癌脑转移放射治疗的预后因素分析［J］. 安徽医药, 2012, 16(8): 1136-1139. ［27］黄福献, 郑艳, 买买提江·卡斯木, 等. 颅内转移瘤患者不同个体化治疗方案疗效比较［J］. 吉林大学学报, 2013, 39(4): 828-831. ［28］ Garber ST, Jensen RL. Image guidance for brain metastases resection［J］. Surg Neurol Int, 2012, 3 Suppl 2: S111-117. ［29］ Welsh JW, Komaki R, Amini A, et al. Phase Ⅱ trial of erlotinib plus concurrent wholebrain radiation therapy for patients with brain metastases from nonsmallcell lung cancer［J］. J Clin Oncol, 2013, 31(7): 895-902.

[1]	Wang Zihao, Wang Yu, Yang Xin, He Yi, Mo Xingkui, Yuan Tao.Research progress on the molecular mechanism and related treatments of ferroptosis in osteosarcoma[J]. Journal of International Oncology, 2024, 51(4): 239-244.
[2]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun.Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases[J]. Journal of International Oncology, 2023, 50(3): 138-143.
[3]	Sun Xiaolin, Zhang Zhanyu, Xu Linzong, Liu Yingchao, Li Xiaomei.Potential value of radiotherapy combined with immunotherapy in breast cancer brain metastases[J]. Journal of International Oncology, 2022, 49(4): 243-246.
[4]	Xu Qiuyue, Ma Xianmei, Yue Qi.Immunotherapy for endometrial carcinoma based on molecular typing[J]. Journal of International Oncology, 2022, 49(11): 700-704.
[5]	Shi Yue, Li Shen, Feng Jifeng.Treatment options for colorectal cancer primary lesions with unresectable metastases at risk of acute abdomen[J]. Journal of International Oncology, 2021, 48(11): 693-697.
[6]	Ma Chao, Cai Hongqing, Zhang Minjie, Ye Shilu, Meng Xiaoli, He Jie, Wan Jinghai.Analysis of prognostic factors after surgical operation of lung cancer brain metastases[J]. Journal of International Oncology, 2020, 47(2): 77-81.
[7]	Hu Yanhong, Zhao Guofeng, Wang Donghai.Clinical significance of preoperative platelet count in laryngeal squamous cell carcinoma prognosis[J]. Journal of International Oncology, 2019, 46(2): 82-86.
[8]	Dong Fang, Xue Jincai, Wang Yunsheng, Liu Qinjiang.Progress of external beam radiotherapy for thyroid cancer[J]. Journal of International Oncology, 2019, 46(11): 641-648.
[9]	ZHANG Xiang, ZHUANG Rui.Influences of platelet distribution width on the prognosis of patients with nasopharyngeal cancer[J]. Journal of International Oncology, 2018, 45(5): 257-261.
[10]	Zhou Jin, Wu Jie, Zhang Huibo, Chen Min.Therapy for elderly patients with advanced nonsmall cell lung cancer[J]. Journal of International Oncology, 2018, 45(12): 756-759.
[11]	Chen Yu, Ji Hongchen, Cao Dayong, Li Xiao.Expression and clinical value of NRP-1 in hepatocellular carcinoma[J]. Journal of International Oncology, 2017, 44(6): 428-.
[12]	Chen Dalei, Shen Yanyan, Lin Chuanqi, Wang Xiaohui, Shi Hao, Guo Guilong.Treatment protocols of local-regional recurrence after breast cancer surgery[J]. Journal of International Oncology, 2017, 44(12): 929-932.
[13]	Chen Yue, Xiao Su, Pan Wei.Application of preoperative neoadjuvant chemotherapy in cervical cancer patients undergoing surgical treatment[J]. Journal of International Oncology, 2017, 44(10): 749-753.
[14]	Cui Jing, Tan Hui, Jiang Lei, Yuan Wenzhen, Guan Quanlin.Association between XPC Lys939Gln(A/C) gene polymorphism and the susceptibility of gastric cancer: a Metaanalysis[J]. Journal of International Oncology, 2016, 43(8): 597-602.
[15]	Pan Zhongya, Long Xinghua.Breast cancer metastasis suppressor gene 1 correlates with progression of cancer: a Metaanalysis[J]. Journal of International Oncology, 2016, 43(8): 603-608.